Sentence examples for marker for minimal from inspiring English sources

Moreover, miR-3151 can be particularly useful among patients without NPM1 mutations, who lack an universal molecular marker for minimal residual disease monitoring as NPM1mut AML patients.

Only future experiments will define whether the DNA fusion or the RNA fusion will be the better marker for minimal residual diseases or early recurrence.

This experiment demonstrates that donor templates can be designed for the incorporation of discontinuous exogenous DNA sequences an approach that enables careful placement of the visible marker for minimal disruption.

High plasma expression levels of miR-375 were found to be a sensitive marker for minimal residual disease with circulating tumor cells and specifically discriminate between metastatic BC patients and healthy controls [ 18, 48].

Sir, In a recently published paper in your journal Nissan et al (2006), following the commonly used definition, described 'a molecule expressed in all tumour cells but not in normal human tissues' as an ideal marker for minimal residual disease detection.

Isolated disseminated tumour cells (DTC) are regarded as surrogate markers for minimal residual disease in breast cancer.

Disseminated tumor cells (DTC) in the bone marrow (BM) and circulating tumor cells (CTC) in blood are suggested as potential surrogate markers for minimal residual disease, the precursor of metastatic disease.

Besides the observation that DCX is a marker for the minimal residual disease in human neuroblastoma [ 6], our results provides the new evidence that this protein is not present in all cell subtypes composing SK-N-SH cell line but it is express only in the more aggressive neuroblastoma cell subpopulation and in the retinoic acid-resistant cells that possess high motility and invasiveness.

BACKGROUND: The study was undertaken to develop a potential new markers for distinguishing minimal change nephrotic syndrome (MCNS) and focal segmental glomerulosclerosis (FSGS) in children.

The genomic fusion site, unique to individual patients and specific for the malignant clone, represents an ideal molecular marker for quantification of minimal residual disease.

Gerber et al. found that ASCs population could be divided according to the aldehyde dehydrogenase activity and CD34+CD38- fraction with high levels of aldehyde dehydrogenase activity was a potential marker for clinically significant minimal residual disease in AML [ 19].